Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 5/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.31 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5529411 | 0.68 | CYP3A4 (0.36) | CHRM2CYP2D6KCNA5KCNN4 | |
| SCHEMBL9118898 | 0.67 | CYP19A1 (0.39) | CYP19A1CYP2D6KCNA5 | |
| SCHEMBL13505959 | 0.66 | CYP19A1 (0.46) | CYP19A1CHRM2KCNA5 | |
| SCHEMBL28680178 | 0.65 | CYP19A1 (0.49) | CYP19A1KCNA5 | |
| SCHEMBL11685815 | 0.64 | CYP19A1 (0.71) | CYP19A1KCNA5 | |
| SCHEMBL11264781 | 0.63 | CYP19A1 (0.44) | CYP19A1KCNA5 | |
| SCHEMBL11628919 | 0.62 | CYP19A1 (0.43) | CYP19A1KCNA5 | |
| SCHEMBL9658903 | 0.61 | CYP19A1 (0.49) | CYP19A1KCNA5 | |
| SCHEMBL9661803 | 0.61 | CYP19A1 (0.49) | CYP19A1KCNA5 | |
| SCHEMBL8938124 | 0.60 | CYP19A1 (0.44) | CYP19A1KCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225287-A1 | Substituted Arylpyrazines | YOON TAEYOUNG | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225287-A1 | Substituted Arylpyrazines | CRHR1, CRHR2, CRH | CYP19A1 2020/4885CHRM2 461/4885BLM 4602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.